Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

RSS icon
Example of an FFR-angio image-derived hemodynamic flow model performed tableside in the cath lab reconstructed using three different C-arm contract image acquisitions. This technology from CathWorks, which was recently acquired by Medtronic, can eliminate the need for pressure wires and adenosine to assess FFR pressures. These measurements are used to determine the hemodynamic significance of a stenosis and determine if a stent is necessary or if a patient can be treated medically.

PHOTO GALLERY: ACC.23 in New Orleans

Browse a selection of photos from the American College of Cardiology's annual meeting in New Orleans. The pictures highlight key moments, new technologies and much more from the big show. 

Sphere-9 mapping and ablation catheter

Medtronic gains key approval for new mapping and ablation system

Medtronic acquired the technology in a 2022 deal reportedly worth $925 million.

cardiologist patient heart compensation starting salary 2022 interventional cardiologist

Pulsed-field ablation for AFib not linked to any signs of bronchial damage

As this new ablation technique continues to gain momentum, researchers are hoping to learn as much as possible about any potential side effects. 

Shockwave L6 Peripheral IVL Catheter Shockwave Medical

Shockwave Medical launches new IVL catheter for challenging lesions in US

After its initial release was limited to certain customers, the new-look catheter is now available in four different sizes throughout the United States.

Advanced imaging does not always improve outcomes, data suggest

Although advanced imaging exams have proven benefits in defining disease severity, new data indicate that more sophisticated studies might not impact outcomes as much as previously thought. 

Paul Sorajja, MD, director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Abbott Northwestern Hospital, was the principal investigator for the late-breaking TRILUMINATE pivotal trial at the American College of Cardiology (ACC) 2023 meeting and explains details of this landmark trial. #ACC #ACC23 #triluminate

TRILUMINATE trial may pave the way for FDA clearance for tricuspid valve clip device

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

Links to all the American College of Cardiology late-breaking studies for ACC.23

Here are links to more information on every late-breaking presentation at ACC.23.

ACC 2023 program chair Douglas Drachman, MD, explains the top takeaways from the American College of Cardiology meeting. #ACC #ACC23

Key takeaways from the ACC 2023 annual meeting

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

Displaying 1065 - 1072 of 2125
Design by Adaptive Theme